Article | Published:

The safety and efficacy of clofarabine in combination with high-dose cytarabine and total body irradiation myeloablative conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults (CAYA) with poor-risk acute leukemia

Bone Marrow Transplantation (2018) | Download Citation

Abstract

Acute leukemias in children with CR3, refractory relapse, or induction failure (IF) have a poor prognosis. Clofarabine has single agent activity in relapsed leukemia and synergy with cytarabine. We sought to determine the safety and overall survival in a Phase I/II trial of conditioning with clofarabine (doses 40 – 52 mg/m2), cytarabine 1000 mg/m2, and 1200 cGy TBI followed by alloSCT in children, adolescents, and young adults with poor-risk leukemia. Thirty-seven patients; Age 12 years (1–22 years); ALL/AML: 34:3 (18 IF, 10 CR3, 13 refractory relapse); 15 related, 22 unrelated donors. Probabilities of neutrophil, platelet engraftment, acute GvHD, and chronic GvHD were 94%, 84%, 49%, and 30%, respectively. Probability of day 100 TRM was 8.1%. 2-year EFS (event free survival) and OS (overall survival) were 38.6% (CI95: 23–54%), and 41.3% (CI95: 25–57%). Multivariate analysis demonstrated overt disease at time of transplant (relative risk (RR) 3.65, CI95: 1.35–9.89, P = 0.011) and umbilical cord blood source (RR 2.17, CI95: 1.33–4.15, P = 0.019) to be predictors of worse EFS/OS. This novel myeloablative conditioning regimen followed by alloSCT is safe and well tolerated in CAYA with very poor-risk ALL or AML. Further investigation in CAYA with better risk ALL and AML undergoing alloSCT is warranted.

  • Subscribe to Bone Marrow Transplantation for full access:

    $902

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

References

  1. 1.

    Reismuller B, Peters C, Dworzak MN, Potschger U, Urban C, Meister B, et al. Outcome of children and adolescents with a second or third relapse of acute lymphoblastic leukemia (ALL): a population-based analysis of the Austrian ALL-BFM (Berlin-Frankfurt-Munster) study group. J Pediatr Hematol Oncol. 2013;35:e200–204.

  2. 2.

    Faderl S, Gandhi V, O’Brien S, Bonate P, Cortes J, Estey E, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 2005;105:940–7.

  3. 3.

    Kaspers G. How I treat paediatric relapsed acute myeloid leukaemia. Br J Haematol. 2014;166:636–45.

  4. 4.

    Thomas X, de Botton S, Chevret S, Caillot D, Raffoux E, Lemasle E, et al. Randomized phase II study of clofarabine-based consolidation for younger adults with acute myeloid leukemia in first remission. J Clin Oncol. 2017;35:1223–30.

  5. 5.

    Shereck EB, Cooney E, van de Ven C, Della-Lotta P, Cairo MS. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients. Pediatr Blood Cancer. 2007;49:306–12.

  6. 6.

    Geyer MB, Jacobson JS, Freedman J, George D, Moore V, van de Ven C, et al. A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients. Br J Haematol. 2011;155:218–34.

  7. 7.

    Bhatia M, Militano O, Jin Z, Figurski M, Shaw L, Moore V, et al. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2010;16:333–43.

  8. 8.

    Cahn JY, Klein JP, Lee SJ, Milpied N, Blaise D, Antin JH, et al. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood. 2005;106:1495–1500.

  9. 9.

    Cooper TM, Alonzo TA, Gerbing RB, Perentesis JP, Whitlock JA, Taub JW, et al. AAML0523: a report from the Children’s Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia. Cancer. 2014;120:2482–9.

  10. 10.

    Cooper TM, Razzouk BI, Gerbing R, Alonzo TA, Adlard K, Raetz E, et al. Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2013;60:1141–7.

  11. 11.

    Oliansky DM, Camitta B, Gaynon P, Nieder ML, Parsons SK, Pulsipher MA, et al. Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. Biol Blood Marrow Transplant. 2012;18:505–22.

  12. 12.

    Nemecek ER, Ellis K, He W, Bunin NJ, Bajwa RS, Cheerva A, et al. Outcome of myeloablative conditioning and unrelated donor hematopoietic cell transplantation for childhood acute lymphoblastic leukemia in third remission. Biol Blood Marrow Transplant. 2011;17:1833–40.

  13. 13.

    Schrappe M, Hunger SP, Pui CH, Saha V, Gaynon PS, Baruchel A, et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med. 2012;366:1371–81.

  14. 14.

    Jeha S, Razzouk B, Rytting M, Rheingold S, Albano E, Kadota R, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Oncol. 2009;27:4392–7.

  15. 15.

    Hijiya N, Gaynon P, Barry E, Silverman L, Thomson B, Chu R, et al. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia. 2009;23:2259–64.

  16. 16.

    Middeke JM, Herbst R, Parmentier S, Bug G, Hanel M, Stuhler G, et al. Long-term follow-up and impact of comorbidity before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory acute myeloid leukemia-lessons learned from the prospective BRIDGE trial. Biol Blood Marrow Transplant. 2017;23:1491–7.

  17. 17.

    Locke F, Agarwal R, Kunnavakkam R, van Besien K, Larson RA, Odenike O, et al. A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes. Bone Marrow Transplant. 2013;48:1437–43.

  18. 18.

    Spitzer B, Perales MA, Kernan NA, Prockop SE, Zabor EC, Webb N, et al. Second allogeneic stem cell transplantation for acute leukemia using a chemotherapy-only cytoreduction with clofarabine, melphalan, and thiotepa. Biol Blood Marrow Transplant. 2016;22:1449–54.

  19. 19.

    Mohty M, Malard F, Blaise D, Milpied N, Socie G, Huynh A, et al. Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia. Haematologica. 2017;102:184–91.

  20. 20.

    Kebriaei P, Bassett R, Lyons G, Valdez B, Ledesma C, Rondon G, et al. Clofarabine plus busulfan is an effective conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia: long-term study results. Biol Blood Marrow Transplant. 2017;23:285–92.

  21. 21.

    Magenau J, Westervelt P, Khaled S, McGuirk J, Hari P, Eapen M, et al. A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2017;52:59–65.

  22. 22.

    El-Jawahri A, Li S, Ballen KK, Cutler C, Dey BR, Driscoll J, et al. Phase II trial of reduced-intensity busulfan/clofarabine conditioning with allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoid leukemia. Biol Blood Marrow Transplant. 2016;22:80–85.

  23. 23.

    Chevallier P, Labopin M, Socie G, Tabrizi R, Furst S, Lioure B, et al. Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial. Haematologica. 2014;99:1486–91.

  24. 24.

    Soni S, Abdel-Azim H, McManus M, Nemecek E, Sposto R, Woolfrey A, et al. Phase I study of clofarabine and 2-Gy total body irradiation as a nonmyeloablative preparative regimen for hematopoietic stem cell transplantation in pediatric patients with hematologic malignancies: a therapeutic advances in childhood leukemia consortium study. Biol Blood Marrow Transplant. 2017;23:1134–41.

  25. 25.

    Bader P, Salzmann-Manrique E, Balduzzi A, Dalle J-H, Woolfrey AE, Bar M, et al. Monitoring of minimal residual disease before and after allogeneic stem cell transplantation childhood ALL - a retrospective assessment on behalf of the PDWP of the EBMT, the COG, PBMTC, the I-BFM and the Westhafen-Intercontinental-Group. Blood. 2016;128:985–985.

  26. 26.

    Chen YB, Wang T, Hemmer MT, Brady C, Couriel DR, Alousi A, et al. GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes. Bone Marrow Transplant. 2017;52:400–8.

Download references

Acknowledgements

We would like to thank Erin Morris, RN, and Virginia Davenport, RN for their expert editorial assistance, the PBMTC chair, Michael Pulsipher, MD, and the PBMTC Oncology Committee for their support and all the patients and families that participated in this study. We would also like to thank the external Data Safety Monitoring Board members for their expert advice and review of this clinical trial (Chair, Sima Jeha, MD; Roger Giller, MD and Koen Van Biesen, MD). This research was supported in part by grants from the Pediatric Cancer Research Foundation, Doris Duke Charitable Foundation and Genzyme.

Author information

Affiliations

  1. Departments of Pediatrics, Valhalla, NY, USA

    • Jessica Hochberg
    • , Nan Chen
    • , Lauren Harrison
    • , Olga Militano
    • , M. Fevzi Ozkaynak
    •  & Mitchell S. Cairo
  2. Pediatric Institute, Cleveland Clinic Children’s, Cleveland, Ohio, USA

    • Stacey Zahler
  3. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    • Mark B. Geyer
  4. Department of Pediatrics, Hackensack University Medical Center, Hackensack, NJ, USA

    • Jennifer Krajewski
    •  & Alfred P. Gillio
  5. Department of Pediatrics, University of Louisville, Louisville, KY, USA

    • Alexandra C. Cheerva
  6. Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA

    • Julie Talano
  7. Department of Pediatrics, University of California at Los Angeles, Los Angeles, CA, USA

    • Theodore B. Moore
  8. Department of Hematology/Oncology, Children’s Hospital and Research Center of Oakland, Oakland, CA, USA

    • Mark C. Walters
  9. Department of Pathology and Laboratory Medicine, Children’s Hospital Los Angeles, Los Angeles, CA, USA

    • Lee Ann Baxter-Lowe
  10. Departments of Microbiology and Immunology, Valhalla, NY, USA

    • Carl Hamby
    •  & Mitchell S. Cairo
  11. Departments of Medicine, Valhalla, NY, USA

    • Mitchell S. Cairo
  12. Departments of Pathology, Valhalla, NY, USA

    • Mitchell S. Cairo
  13. Departments of Cell Biology and Anatomy, New York Medical College, Valhalla, NY, USA

    • Mitchell S. Cairo

Authors

  1. Search for Jessica Hochberg in:

  2. Search for Stacey Zahler in:

  3. Search for Mark B. Geyer in:

  4. Search for Nan Chen in:

  5. Search for Jennifer Krajewski in:

  6. Search for Lauren Harrison in:

  7. Search for Olga Militano in:

  8. Search for M. Fevzi Ozkaynak in:

  9. Search for Alexandra C. Cheerva in:

  10. Search for Julie Talano in:

  11. Search for Theodore B. Moore in:

  12. Search for Alfred P. Gillio in:

  13. Search for Mark C. Walters in:

  14. Search for Lee Ann Baxter-Lowe in:

  15. Search for Carl Hamby in:

  16. Search for Mitchell S. Cairo in:

Conflict of interest

M.B.G. reports grants and non-financial support from Doris Duke Charitable Foundation, during the conduct of the study; and grants from Lymphoma Research Foundation, grants from NIH/National Center for Advancing Translational Sciences, outside the submitted work. The remaining authors declare that they have no conflict of interest.

Corresponding author

Correspondence to Mitchell S. Cairo.

Electronic supplementary material

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/s41409-018-0247-9

Rights and permissions

To obtain permission to re-use content from this article visit RightsLink.